Used in cancer immunotherapy to target tumor-associated macrophages by blocking the CSF1 receptor, thereby inhibiting macrophage survival and recruitment into the tumor microenvironment. This helps enhance anti-tumor immune responses and is being investigated in combination with other immunotherapies such as checkpoint inhibitors. Also applied in research settings to study macrophage biology and the role of CSF1R signaling in diseases including cancer, inflammatory disorders, and bone diseases.